Most Similar Insulin to Novolin NPH
The most similar insulin to Novolin NPH is Humulin NPH, as both are neutral protamine Hagedorn (NPH) intermediate-acting human insulins with identical pharmacokinetic profiles and clinical effects. 1
Direct NPH Equivalents
Humulin NPH is the direct equivalent to Novolin NPH, differing only in manufacturer (Eli Lilly vs. Novo Nordisk), with both being intermediate-acting human insulins that can be substituted unit-for-unit. 1
Both NPH formulations have the same onset of action (approximately 1-2 hours), peak action (6-8 hours), and duration (approximately 12 hours). 2
If switching between NPH brands, the same insulin formulation from another manufacturer may be substituted without dose adjustment, though this should ideally be done under medical supervision. 1
Important Caveat About NPH Characteristics
NPH insulin is not truly a basal or peakless insulin despite being classified as intermediate-acting basal insulin—it has a pronounced peak action that occurs 6-8 hours after injection, which increases hypoglycemia risk during peak times, particularly after nighttime injection. 3, 4
The peak action profile of NPH distinguishes it fundamentally from modern long-acting analogs like glargine or degludec, which provide peakless basal coverage. 2, 5
Long-Acting Analogs as Functional Alternatives (Not Similar, But Better)
While you asked for the most similar insulin, it's critical to understand that long-acting insulin analogs (glargine, detemir, degludec) are functionally superior alternatives to NPH for basal insulin replacement, though they are pharmacologically different:
Insulin glargine provides a peakless, 24-hour basal profile that more closely mimics physiologic basal insulin secretion than NPH's peaked action. 2, 6, 5
Long-acting analogs reduce nocturnal hypoglycemia risk by 31% (OR 0.69) and severe hypoglycemia risk by 27% (OR 0.73) compared to NPH. 7
Conversion from NPH to glargine or other long-acting analogs can typically be done unit-for-unit, with subsequent titration based on glucose monitoring. 8
Cost Considerations
NPH insulin remains the most affordable basal insulin option at approximately $25-165 per vial, making it appropriate for cost-constrained situations when hypoglycemia risk is not elevated. 8, 3
Biosimilar glargine costs approximately $118-323 per 1,000 units, representing a middle ground between NPH and branded long-acting analogs. 8